CRT is the partner of choice for pharmaceutical and biotechnology companies seeking to in-license new cancer therapeutic or diagnostic opportunities. This is in part due to our exclusive access to many of the world's leading authorities in cancer research and our applied development capabilities.  CRT has forged many long-standing, successful relationships with various prestigious international research institutes and charities. These relationships, alongside that of Cancer Research UK, provide for an outstanding research base ensuring that our commercial partners have access to some of the most ground-breaking developments in cancer research.

Companies working with CRT can be assured that potential collaboration and licensing opportunities have been rigorously pre-screened and represent some of the most exciting opportunities in oncology.  CRT ensures that all inventions have been progressed as far as possible for rapid onward development, and that discoveries include well-researched and broad patents, validated targets, robust, industrially-applicable drug discovery assays and lead compounds that have been validated in cellular assays, or in vivo.  Where viable, new drug candidates will have also been through early pharmacology and toxicology studies.

CRT’s success is founded on our multidisciplinary teams. In addition to in-house legal, patenting and marketing expertise, the company features teams of business managers, all with an intimate understanding of cancer research and the specific needs and interests of oncology-focused companies.  These capabilities are reinforced further by CRT's Development Laboratories, with core competences in molecular and cellular biology, drug discovery, medicinal chemistry and early pharmacology. The laboratory plays a crucial role within CRT in adding value to a scientist's initial invention, enhancing its potential for commercialisation and therefore cancer patient benefit.  As a result, companies working with CRT can be assured that they will receive exceptional service from professionals who understand the oncology market. 

In summary, CRT can offer its commercial partners:

• Unique access to ground-breaking developments in cancer research from the leading institutions in the UK, Europe and the USA;
• A 'one stop shop' for oncology licensing, in particular for the UK where CRT manages in excess of 80% of all opportunities from public institutions;
• An in-depth understanding of the needs and deal-making parameters of pharmaceutical and biotechnology companies;
• Technology that has been appropriately packaged and developed for rapid onward development;
• Experience in establishing effective research collaborations;
• A single point of negotiation, with in-house legal and patenting teams, ensuring all transactions are dealt with in an efficient manner;
• Strong business development credibility amongst a global network of oncology-focused pharmaceutical and biotechnology companies.